Author + information
- Received February 11, 1991
- Revision received May 9, 1991
- Accepted May 21, 1991
- Published online November 15, 1991.
- ↵∗Address for reprints: Joseph Loscalzo, MD. Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
Organic nitrates, cornerstones of antianginal therapy, are believed to exert their principal anti-ischemic benefit by relaxing vascular smooth muscle. Recent evidence suggests that these compounds and related nitro(so) vasodilators are also potent platelet inhibitors. In view of the well recognized role of thrombotic events mediated by platelets in acute coronary syndromes, the antiplatelet effect of nitrates may also be of mechanistic importance in the treatment of these disorders. This review details the biochemical mechanism by which nitro(so) compounds inhibit platelet function and summarizes the in vitro and in vivo evidence that supports their antithrombotic effects.
↵1 Dr. Stamler is the recipient of National Research Service Award HL 01877 from the National Institutes of Health.
↵2 Dr. Loscalzo is the recipient of Research Career Development Award HL 02273 from the National Institutes of Health.
☆ This study was supported in part by Grants HL 40411 and HL 43344 from the National Institutes of Health, Bethesda, Maryland; a Merit Review Award from the Veterans Administration, Boston, Massachusetts and a Grant-in-Aid from the American Heart Association, Dallas, Texas with funds contributed in part by the Massachusetts Affiliate.
- Received February 11, 1991.
- Revision received May 9, 1991.
- Accepted May 21, 1991.